Abstract Compounding pharmacies play an important role not only in compounding personalized formulations, but also preparing drugs at the same concentration and dosage as those from commercial manufacturers. The excipients used in compounding are generally standardized for many drugs, however they do not consider the intrinsic properties, such as the poor water solubility, of each substance. The excipient performance of commercially available compounded furosemide capsules in 7 compounding pharmacies from Manaus was evaluated and compared them to the performance of the reference medicinal product (Lasix® tablets) and 2 batches of capsules made in-house (T2 and T4) with a standardized excipient. All batches were subjected to tests for weight variation, assay, uniformity of dosage units, disintegration and dissolution profile. Of the 7 different compound formulas acquired in the compounding pharmacies, only 2 passed all tests. Most formulas passed the tests for weight determination, disintegration time and assay, however batches from 2 establishments failed in regards to the uniformity of the content and 5 batches failed the dissolution test. The reference medicinal product was approved in all tests, as were the T2 capsules made in-house with drug-excipient ratio 1:2. These results confirm the importance of the excipient composition, especially for poorly soluble drugs.

A validation study of an UV spectrophotometric method was conducted for quantitative analysis of benznidazol (BZN) in a lipid. The analytical determinations were performed at 315 nm at 25 ºC. The emulsion components did not interfere on drug analyses, demonstrating the specificity of the methodology. A good linearity (r = 0.99995) and precision (RSD < 5.0%) for intra and inter-day studies, including the reproducibility test were observed. The accuracy ranged of 102.1 + 2.8 e 103.8 + 1.7%. The statistical analysis demonstrates a linear, precise, accurate and robust method for BZN quantification from the lipid emulsion system.